Citadel Advisors
ETTX

Citadel Advisors’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Citadel Advisors’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,197
Closed -$22K – 15153
2021
Q4 		$22K Buy
+10,197
New +$27.6K ﹤0.01% 13574
2021
Q2 		– Sell
-68,574
Closed -$147K – 14784
2021
Q1 		$147K Buy
68,574
+14,458
+27% +$41.1K ﹤0.01% 12069
2020
Q4 		$134K Buy
+54,116
New +$106K ﹤0.01% 10017

Other funds holding ETTX

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Citadel Advisors's ETTX Position: Q1 2022 in Review

Citadel Advisors sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q1 2022, closing a stake of 10,197 shares — an estimated $22K sold.

Citadel Advisors first reported a position in ETTX in Q4 2020 and held it in 3 quarters. The position peaked at $147K in Q1 2021. 22 funds tracked by Wall St. Rank hold ETTX as of Q1 2022.

  • Citadel Advisors reported no remaining Entasis Therapeutics Holdings Inc. position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 10,197 Entasis Therapeutics Holdings Inc. shares in Q1 2022, an estimated $22K.
  • Citadel Advisors first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2020 and held it in 3 quarters.
  • Citadel Advisors's Entasis Therapeutics Holdings Inc. position peaked at $147K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.